
Figure 1.
Structure of coixol (A) and adlay seeds (B).

Figure 2.
Effects of coixol alone upon cell viability. NGF-differentiated PC12 cells were treated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, or 32 μM for 48 h. Normal group had no coixol. Data are expressed as mean ± SD (n = 8). †: P < 0.05 compared the normal; ‡: P < 0.05 compared coixol 8; §: P < 0.05 compared coixol 16; #: P < 0.05 compared coixol 32. NGF, nerve growth factor; SD, standard deviation.

Figure 3.
Effects of coixol on cell viability, Bcl-2 mRNA expression, and Bax mRNA expression. NGF-differentiated PC12 cells were pretreated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, or 2 μM for 48 h, followed by Abeta25-35 exposure for 24 h. Normal groups had no coixol or Abeta25-35. Abeta groups had no coixol, but with Abeta25-35. Data are expressed as mean ± SD (n = 8). a: P < 0.05 compared the normal; b: P < 0.05 compared Abeta; c: P < 0.05 compared coixol 0.125 + Abeta; d: P < 0.05 compared coixol 0.25 + Abeta; e: P < 0.05 compared coixol 0.5 + Abeta; and f: P < 0.05 compared coixol 1 + Abeta. NGF, nerve growth factor; SD, standard deviation.

Figure 4.
Effects of coixol on intracellular Ca2+ level. NGF-differentiated PC12 cells were pretreated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, or 2 μM for 48 h, followed by Abeta25-35 exposure for 24 h. Intracellular Ca2+ level was measured at 0 h, 12 h, and 24 h. Normal groups had no coixol or Abeta25-35. Abeta groups had no coixol, but with Abeta25-35. Data are expressed as mean ± SD (n = 8). a: P < 0.05 compared the normal; b: P < 0.05 compared Abeta; c: P < 0.05 compared coixol 0.125 + Abeta; d: P < 0.05 compared coixol 0.25 + Abeta; e: P < 0.05 compared coixol 0.5 + Abeta; and f: P < 0.05 compared coixol 1 + Abeta. NGF, nerve growth factor; SD, standard deviation.
Table 1.
Effects (% of normal groups) of coixol on MMP, Na+-K+ ATPase, and caspase-3 activities
| MMP | Na+-K+ ATPase | Caspase-3 | |
|---|---|---|---|
| Normal | 100 | 100 | 100 |
| Abeta | 25 ± 5* | 30 ± 3* | 337 ± 19* |
| Coixol, 0.125 + Abeta | 29 ± 3* | 39 ± 2*,** | 315 ± 23* |
| Coixol, 0.25 + Abeta | 38 ± 4*,**,*** | 44 ± 5*,** | 276 ± 11*,**,*** |
| Coixol, 0.5 + Abeta | 49 ± 3*,**,***,# | 56 ± 2*,**,***,# | 230 ± 13*,**,***,# |
| Coixol, 1 + Abeta | 60 ± 5*,**,***,#,## | 68 ± 3*,**,***,#,## | 183 ± 8*,**,***,#,## |
| Coixol, 2 + Abeta | 71 ± 6*,**,***,#,##,### | 74 ± 5*,**,***,#,## | 172 ± 12*,**,***,#,## |

Figure 5.
Effects of coixol on NF-κB binding activity. NGF-differentiated PC12 cells were pretreated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, or 2 μM for 48 h, followed by Abeta25-35 exposure for 24 h. Normal groups had no coixol or Abeta25-35. Abeta groups had no coixol, but with Abeta25-35. Data are expressed as mean ± SD (n = 8). a: P < 0.05 compared the normal; b: P < 0.05 compared Abeta; c: P < 0.05 compared coixol 0.125 + Abeta; d: P < 0.05 compared coixol 0.25 + Abeta; e: P < 0.05 compared coixol 0.5 + Abeta; and f: P < 0.05 compared coixol 1 + Abeta. NF-κB, nuclear factor kappa B; NGF, nerve growth factor; SD, standard deviation.
Table 2.
Effects of coixol on the levels or activities of ROS, 8-OHdG, GSH, GPX, GR, and catalase
| ROS RFU/mg protein | 8-OHdG ng/mg protein | GSH ng/mg protein | GPX U/mg protein | GR U/mg protein | Catalase U/mg protein | |
|---|---|---|---|---|---|---|
| Normal | 0.13 ± 0.04 | 0.43 ± 0.06 | 88 ± 5 | 72.1 ± 1.7 | 62.8 ± 1.1 | 70.4 ± 1.9 |
| Abeta | 3.11 ± 0.21* | 2.72 ± 0.10* | 26 ± 2* | 30.2 ± 0.9* | 27.6 ± 0.7* | 24.1 ± 1.0* |
| Coixol, 0.125 + Abeta | 2.72 ± 0.14* | 2.51 ± 0.15* | 29 ± 4* | 32.5 ± 1.2* | 29.0 ± 1.2* | 30.5 ± 0.8*,** |
| Coixol, 0.25 + Abeta | 2.15 ± 0.08*,**,*** | 2.02 ± 0.07*,**,*** | 36 ± 3*,**,*** | 43.1 ± 1.0*,**,*** | 37.1 ± 1.0*,**,*** | 39.3 ± 1.2*,**,*** |
| Coixol, 0.5 + Abeta | 1.64 ± 0.15*,**,***,# | 1.73 ± 0.11*,**,***,# | 49 ± 5*,**,***,# | 52.4 ± 1.3*,**,***,# | 45.3 ± 0.9*,**,***,# | 48.4 ± 1.5*,**,***,# |
| Coixol, 1 + Abeta | 1.03 ± 0.17*,**,***,#,## | 1.36 ± 0.08*,**,***,#,## | 60 ± 4*,**,***,#,## | 55.0 ± 2.1*,**,***,# | 53.2 ± 1.4*,**,***,#,## | 55.9 ± 1.1*,**,***,#,## |
| Coixol, 2 + Abeta | 0.87 ± 0.09*,**,***,#,## | 1.13 ± 0.13*,**,***,#,## | 71 ± 3*,**,***,#,##,### | 62.7 ± 1.4*,**,***,# | 55.3 ± 0.8*,**,***,#,## | 60.3 ± 0.9*,**,***,#,## |

Figure 6.
Effects of coixol on protein expression of phosphorylated NF-κB p65, phosphorylated p38, iNOS, RAGE, and Nrf2. NGF-differentiated PC12 cells were pretreated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, or 2 μM for 48 h, followed by Abeta25-35 exposure for 24 h. Normal groups had no coixol or Abeta25-35. Abeta groups had no coixol, but with Abeta25-35. Data are expressed as mean ± SD (n = 8). a: P < 0.05 compared the normal; b: P < 0.05 compared Abeta; c: P < 0.05 compared coixol 0.125 + Abeta; d: P < 0.05 compared coixol 0.25 + Abeta; e: P < 0.05 compared coixol 0.5 + Abeta; and f: P < 0.05 compared coixol 1 + Abeta. iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor kappa B; NGF, nerve growth factor; RAGE, receptor of advanced glycation end product; SD, standard deviation.
Table 3.
Effects (pg/mg protein) of coixol on the levels of TNF-α, IL-1β, IL-6, and PGE2
| TNF-α | IL-1β | IL-6 | PGE2 | |
|---|---|---|---|---|
| Normal | 12 ± 3 | 7 ± 2 | 9 ± 3 | 109 ± 8 |
| Abeta | 261 ± 14* | 199 ± 13* | 204 ± 9* | 442 ± 23* |
| Coixol, 0.125 + Abeta | 229 ± 10*,** | 162 ± 11*,** | 170 ± 10*,** | 386 ± 17*,** |
| Coixol, 0.25 + Abeta | 185 ± 9*,**,*** | 120 ± 8*,**,*** | 131 ± 8*,**,*** | 319 ± 12*,**,*** |
| Coixol, 0.5 + Abeta | 136 ± 12*,**,***,# | 84 ± 10*,**,***,# | 97 ± 6*,**,***,# | 257 ± 20*,**,***,# |
| Coixol, 1 + Abeta | 99 ± 7*,**,***,#,## | 61 ± 6*,**,***,#,## | 72 ± 5*,**,***,#,## | 192 ± 8*,**,***,#,## |
| Coixol, 2 + Abeta | 90 ± 5*,**,***,#,## | 52 ± 4*,**,***,#,## | 68 ± 4*,**,***,#,## | 177 ± 9*,**,***,#,## |